Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2
04. Januar 2022 08:30 ET
|
ARCA biopharma, Inc.
Clinically important bradycardia is common in heart failure (HF) patients with persistent or paroxysmal atrial fibrillation (AF)In a Phase 2B clinical trial, the prevalence of clinically important...
ARCA Biopharma President and CEO Dr. Michael Bristow to Present at HFSA 2019 Excellence in Translational Science Symposium
12. September 2019 08:30 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Sept. 12, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
Arca Biopharma Announces Gencaro Atrial Fibrillation Clinical Data Selected for Presentation at HFSA 2019 Scientific Meeting
11. September 2019 08:30 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Sept. 11, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA biopharma Announces Submission of Patent Application to U.S. Patent and Trademark Office Covering Treatment of Atrial Fibrillation in Patients With Heart Failure
13. Mai 2019 09:00 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., May 13, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
Identification of Phosphodiesterease 3A Polymorphism With Potential to Increase Effectiveness of PDE3 Inhibitors Published in the Journal of the American College of Cardiology
18. März 2019 08:30 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., March 18, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
Dose Response of Beta-Blockers in Adrenergic Receptor Polymorphism Genotypes Paper Published in Circulation: Genomic and Precision Medicine
06. März 2019 08:00 ET
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., March 06, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...